Cogent Biosciences (COGT) 44th Annual J.P. Morgan Healthcare Conference summary

Strategic outlook and financial position

• Focused on launching Bezuclastinib in the U.S. in the second half of 2026, with all three NDAs submitted in the first half of the year.

• Maintains a strong balance sheet with $900 million, providing a cash runway into 2028 and supporting commercialization and pipeline expansion.

• Building a commercial team of about 100 employees, emphasizing access and patient engagement for rare diseases.

• Actively considering partnerships for commercialization outside the U.S., with Europe potentially being a direct investment opportunity.

• No need for additional capital anticipated for the foreseeable future.

Clinical trial results and market potential

• Three pivotal trials for Bezuclastinib in GIST and systemic mastocytosis showed positive results, with significant efficacy and tolerability.

• PEAK trial in second-line GIST demonstrated a 16.5-month median progression-free survival and nearly 50% objective response rate, with minimal competition.

• SUMMIT and APEX trials in systemic mastocytosis showed deep reductions in mast cell burden, sustained symptomatic improvement, and high response rates.

• Combined global market opportunities for GIST and systemic mastocytosis estimated at over $8 billion annually, with limited competition.

• Intellectual property protection for Bezuclastinib extends into the mid-2040s, supporting long-term exclusivity.

Pipeline development and future plans

• Advancing a pipeline with a pan-KRAS inhibitor and a highly selective JAK2 V617F inhibitor, both targeting IND in 2026.

• Five internally developed assets expected to enter the clinic by next year, spanning hematology and solid tumor oncology.

• Ongoing studies include a first-line GIST cohort, phase 2 Switch study in Europe for mastocytosis patients switching from avapritinib, and expanded access programs for GIST and SM.

• Pan-KRAS inhibitor CGT1815 shows best-in-class potency and selectivity across KRAS mutations, with strong preclinical efficacy.

• JAK2 V617F inhibitor CGT1145 demonstrates high selectivity and potential as a disease-modifying therapy in preclinical models.